CoChat
Sign Up
PreprintCited by 15SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and HesitancyCOVID-19 Clinical Research Studies

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

At Least Three Doses of Leading Vaccines Essential for Neutralisation of SARS-CoV-2 Omicron Variant

Open access
Singanallur, Nagendrakumar B, van Vuren, Petrus Jansen, McAuley, Alexander J, Bruce, Matthew P, Kuiper, Michael J, Gwini, Stella M, Riddell, Shane, Goldie, Sarah, Drew, Trevor W, Blasdell, Kim R, Tachedjian, Mary, Mangalaganesh, Shruthi, Chahal, Simran, Caly, Leon, Druce, Julian D, Juno, Jennifer A, Kent, Stephen J, Wheatley, Adam K, Vasan, Seshadri S·2022·Frontiers in Immunology
DOI 10.1101/2022.02.20.22271237PMC PMC9152325

Preprint — published as 10.3389/fimmu.2022.883612 · Paper page

Open this paper in CoChat — free account

Abstract

Plasma samples taken at different time points from donors who received either AstraZeneca (Vaxzevria) or Pfizer (Comirnaty) or Moderna (Spikevax) coronavirus disease-19 (COVID-19) vaccine were assessed in virus neutralization assays against Delta and Omicron variants of concern and a reference isolate (VIC31). With the Pfizer vaccine there was 6-8-fold reduction in 50% neutralizing antibody titres (NT 50 ) against Delta and VIC31 at 6 months compared to 2 weeks after the second dose; followed by 25-fold increase at 2 weeks after the third dose. Neutralisation of Omicron was only consistently observed 2 weeks after the third dose, with most samples having titres below the limit of detection at earlier timepoints. Moderna results were similar to Pfizer at 2 weeks after the second dose, while the titres for AstraZeneca samples derived from older donors were 7-fold lower against VIC31 and below the limit of detection against Delta and Omicron. Age and gender were not found to significantly impact our results. These findings indicate that vaccine matching may be needed, and that at least a third dose of these vaccines is necessary to generate sufficient neutralising antibodies against emerging variants of concern, especially Omicron, amidst the challenges of ensuring vaccine equity worldwide.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/2022.02.20.22271237

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 32

  1. 10.3390/v14040800 · DOI
  2. 10.1038/s41541-020-00246-8 · DOI
  3. 10.1021/acsinfecdis.1c00276 · DOI
  4. 10.1007/BF01863914 · DOI
  5. 10.1093/ilar/ilab031 · DOI · Paper page
  6. 10.1063/5.0014475 · DOI
  7. 10.1371/journal.ppat.1010161 · DOI
  8. 10.1056/NEJMoa2104840 · DOI · Paper page
  9. 10.1056/NEJMc2119641 · DOI · Paper page
  10. 10.1056/NEJMc2119236 · DOI · Paper page
  11. 10.1021/acs.jcim.1c01243 · DOI
  12. 10.1038/s41586-022-04479-6 · DOI
  13. 10.1007/s00232-006-0861-0 · DOI
  14. 10.1038/s41586-021-04388-0 · DOI · Paper page
  15. 10.1186/1471-2148-4-21 · DOI · Paper page
  16. 10.7554/eLife.57309 · DOI
  17. 10.1128/JVI.00694-10 · DOI
  18. 2020, Supporting Pandemic Response Using Genomics and Bioinformatics: A Case Study on the Emergent SARS-CoV-2 Outbreak, Transbound Emerg Dis, 67, 1453, 10.1111/tbed.13588 · DOI
  19. 10.2471/BLT.20.253591 · DOI
  20. 10.1016/S2213-2600(22)00010-8 · DOI
  21. 10.1101/2022.02.15.22270948 · DOI
  22. 10.1101/2021.12.20.21267877 · DOI
  23. 10.1101/2021.12.26.21268380 · DOI
  24. 10.1056/NEJMoa2116414 · DOI
  25. 10.1080/22221751.2021.1902245 · DOI
  26. Jayaraman KS . Ferret Chosen as Animal Model to Test Coronavirus Vaccines. Nature India (5 April 2020). Available at: http://go.nature.com/39LGAqx.
  27. 10.1038/s41541-021-00315-6 · DOI
  28. 10.1126/scitranslmed.abh0755 · DOI
  29. 10.1038/nmeth.4067 · DOI
  30. 10.1126/science.abb2507 · DOI · Paper page
  31. 10.1126/science.abb9983 · DOI
  32. 10.1016/0263-7855(96)00018-5 · DOI · Paper page

Metadata

Authors
Singanallur, N. B., van Vuren, P. J., McAuley, A. J., Bruce, M. P., Kuiper, M. J., Gwini, S. M., Riddell, S., Goldie, S., Drew, T. W., Blasdell, K. R., Tachedjian, M., Mangalaganesh, S., Chahal, S., Caly, L., Druce, J. D., Juno, J. A., Kent, S. J., Wheatley, A. K., & Vasan, S. S.
Affiliations
  • Commonwealth Scientific and Industrial Research Organisation (AU)
  • Barwon Health (AU)
  • Victorian Infectious Diseases Reference Laboratory (AU)
  • The University of Melbourne (AU)
Corresponding author
Vasan, Seshadri S
ORCID
Venue
Frontiers in Immunology
Publisher
openRxiv
Published
2022-02-21
Volume
13
Pages
883612-883612
ISSN
1664-3224 (ISSN-L)
DOI
10.1101/2022.02.20.22271237
PMC
PMC9152325
OpenAlex
W4280584659
Cited by
15
References
1
Citations by year
2026: 2 · 2025: 2 · 2024: 2 · 2023: 4 · 2022: 5
FWCI
1.59
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • medRxiv (acceptedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by)
Funders
  • U.S. Department of Health and Human Services
  • Coalition for Epidemic Preparedness Innovations (75F40121C00144)
  • University of Oxford
  • Commonwealth Scientific and Industrial Research Organisation (413322.5)
  • Department of Health, State Government of Victoria
  • State Government of Victoria
  • Barwon Health Foundation
  • U.S. Food and Drug Administration (75F40121C00144, MRF2009092)
  • Food and Drug Administration
  • Medical Research Council
  • National Health and Medical Research Council (1149990, GNT2002073, 75F40121C00144, MRF2009092)
  • Institute of Infection and Immunity
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Social Sciences › Health › Vaccine Coverage and Hesitancy
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Keywords
Omicron variant, COVID-19 vaccines, neutralizing antibodies, third vaccine dose, BNT162b2, Delta variant, vaccine matching, antibody titers, age and gender effects, vaccine equity
MeSH terms
COVID-19, SARS-CoV-2, COVID-19 Vaccines, Humans, Viral Vaccines, Vaccines, Inactivated

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review